Large-scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML
Fabian-Morales, E.; Vallejo Escamilla, D. G.; Gomez, A. A. G.; Rodriguez, A.; Gonzalez-Barrios, R.; Rodriguez-Torres, Y. L.; Henandez, C. C.; de la Torre Lujan, A.; Rico, D. A. O.; Guzman, E. C. O.; Saavedra, A. L.; Frias, S.; Montalvo, L. A. H.
Show abstract
Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm defined by the presence of t(9;22) translocation whose origin has been associated with the tridimensional genome organization. This rearrangement leads to the fusion of BCR and ABL1 genes giving rise to a chimeric protein with constitutive kinase activity. Imatinib, a tyrosine kinase inhibitor (TKI), is used as a first-line treatment for CML, though approximately 40% of CML patients do not respond. Here, using structured illumination microscopy (SIM) and 3D reconstruction, we studied the 3D organization patterns of the ABL1 and BCR genes, and their chromosome territories (CTs) CT9 and CT22, in CD34+ cells from CML patients that responded or not to Imatinib. We found that TKI resistance in CML is associated with high levels of structural disruption of CT9 and CT22 in CD34+ cells, increased CT volumes (especially for CT22), intermingling between CT9 and CT22, and open-chromatin epigenetic mark, in CT22. Altogether our results suggest that large-scale disruption of CT9 and CT22 correlates with the clinical response of CML patients, which could be translated in a potential prognostic marker of response to treatment in this disease and provide novel insights into the mechanisms underlying resistance to TKI in CML.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Stratified computational meta-analysis of 2213 acute myeloid leukemia patients reveals age- and sex-dependent gene expression signatures 91%
- Interplay of IL6 and CRIM1 on thiopurine-induced neutropenia in leukemic patients with wild-type NUDT15 and TPMT 91%
- Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index 91%
Similar papers in this journal
- RAG1 and RAG2 Non-core Regions Are Implicated in Leukemogenesis and Off-target V(D)J Recombination in BCR-ABL1-driven B-cell Lineage Lym-phoblastic Leukemia 91%
- COMPARE, an ultra-fast and robust suite for multiparametric screening, identifies phenotypic drug responses in acute myeloid leukemia 90%
- The chromatin-remodeling enzyme Smarca5 regulates erythrocyte aggregation via Keap1-Nrf2 signaling 89%
Similar papers in this journal
- Cell-to-cell expression dispersion of B-cell surface proteins displays genetic variation among humans 89%
- GFI1 tethers the NuRD complex to open and transcriptionally active chromatin in myeloid progenitors 88%
- Quantitative analysis reveals reciprocal regulations underlying recovery dynamics of thymocytes and thymic environment 88%
Similar papers in this journal
- Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia 92%
- Mutant p53 Drives Clonal Hematopoiesis through Modulating Epigenetic Pathway 91%
- DOT1L inhibition reveals a distinct class ofenhancers dependent on H3K79 methylation 90%
Similar papers in this journal
- Active Receptor Tyrosine Kinases, but not Brachyury, are sufficient to trigger chordoma in zebrafish 89%
- Generation of inducible SMARCAL1 knock-down iPSC to model severe Schimke immune-osseous dysplasia reveals a link between replication stress and altered expression of master differentiation genes 87%
- Standardised imaging pipeline for phenotyping mouse laterality defects and associated heart malformations, at multiple scales and multiple stages 86%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.